The goal is to develop companion diagnostics to match patients with cancer treatments.
The company's set of 10 sequencers brings down genome decoding to $1,000 each.
The company known for Eylea has launched a genetics discovery unit and teamed up with a partner to sequence 100,000 patient genomes.
The diagnostic firm is looking to expand its Cobas HPV diagnostic into first-line use, possibly edging out the older Pap test.
The FDA granted the breast-cancer med "priority review" designation for use in an earlier line of therapy.
Merely isolating genes can't win you a patent, said the Supreme Court -- and that stands to fuel scientific inquiry in the age of personalized medicine
Novartis is advancing its "breakthrough" lung cancer drug into Phase III based on promising Phase I data.
GSK's newest cancer approvals highlight a problem that stalks progress with personalized medicines.
After a skeptical Supreme Court hearing, diagnostics and biopharma patent lawyers are sweating the outcome of Association for Molecular Pathology vs. Myriad Genetics, in which the Court could decide whether or not swatches of genes are patentable.
Diabetes will be the 800-pound gorilla in healthcare for the foreseeable future, according to a crystal ball-gazing white paper from Euro RSCG which pegs the rise of telemedicine, a wave of "cyberchondria" and soaring rates of medical tourism as among the emerging trends reshaping the practice of medicine.
Pfizer Oncology has recruited Desperate Housewives and West Wing star Kathryn Joosten to feature in a national education campaign titled Lung Cancer Profiles, which aims to reduce stigma and plug molecular testing of the disease as the company deepens its investment in genetically-targeted oncology therapies.
The FDA's approval of Pfizer's Xalkori (crizotinib) represents a leap forward for both personalized medicine and Pfizer's R&D turnaround, but its commercial success hinges on a pricey diagnostic array by Abbott's Vysis.